

Edgar Filing: BIOMERICA INC - Form NT 10-Q

BIOMERICA INC  
Form NT 10-Q  
January 14, 2004

U.S. SECURITIES AND EXCHANGE COMMISSION	+-----+
WASHINGTON D.C. 20549	OMB Number
	3235-0058
FORM 12b-25	expires
NOTIFICATION OF LATE FILING	01/31/2002
	SEC File #
	000-
	CUSIP #
	+-----+

check box  
Form 10-KSB [ ]    Form 20-F [ ]    Form 11-K [ ]    Form 10-QSB [x]    Form N-SAR

For Period Ended: November 30, 2003

- Transition Report on Form 10-K
  - Transition Report on Form 20-F
  - Transition Report on Form 11-K
  - Transition Report on Form 10-Q
  - Transition Report on Form N-SAR
- For the Transition Period Ended: \_\_\_\_\_

-----

|  
|Read Instruction (on back page) Before Preparing Form, Please Print or Type|  
|  
| Nothing in this form shall be construed to imply that the Commission has |  
| verified any information contained herein. |  
|

-----  
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:  
-----

-----  
PART I - REGISTRANT INFORMATION  
-----

Full Name of Registrant:  
Biomerica, Inc.

-----  
Former Name if Applicable  
-----

Address of Principal Executive Office (Street and Number)  
1533 Monrovia Avenue

-----  
City, State, Zip Code  
Newport Beach, CA 92663  
-----

-----  
PART II - RULES 12b-25 (b) AND (c)  
-----

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

- XX (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
- (b) The subject annual report, semi-annual report, transition report on Form 10-KSB, Form 20-F, 11-K or Form N-SAR, or portion thereof, will be

Edgar Filing: BIOMERICA INC - Form NT 10-Q

- XX filed on or before the fifteenth calendar day following the prescribed
- due date; or the subject quarterly report of transition report on Form
- 10-QSB, or portion thereof will be filed on or before the fifth
- calendar day following the prescribed due date; and
- (c) The accountant's statement or other exhibit required by Rule 12b-25(c)
- has been attached if applicable.

PART III - NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR or the transition report or portion thereof could not be filed within the prescribed time period.

The Registrant is currently gathering and analyzing certain accounting information and undergoing its periodic quarterly review by its auditors in order to complete its Form 10-QSB. The data and review could not be completed earlier without unreasonable effort and expense.

PART IV - OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification:

Janet Moore	949	645-2111
-----	-----	-----
(Name)	(Area Code)	(Telephone No.)

(2) have all other periodic reports required under section 13 or 15(d) of the Securities Exchange Act of 1934 or section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

Yes [ ]No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

[ ]Yes No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

-----

Biomerica

-----

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Date: January 14, 2004

By: /s/ Zackary S. Irani

Edgar Filing: BIOMERICA INC - Form NT 10-Q

-----  
Zackary S. Irani, Chief Executive Officer

INSTRUCTION; The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form.